Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.53 |
| ▸ | CDC25B | P30305 | 2/20 | 0.53 |
| ▸ | CDC25C | P30307 | 2/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GPR4 | P46093 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | EIF4E | P06730 | 2/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.31 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544438 | 0.88 | CDC25A (0.49) | CDC25ACDC25BCDC25CMALT1 | |
| SCHEMBL3546951 | 0.88 | CDC25A (0.62) | CDC25ACDC25BCDC25CMALT1MAOB | |
| SCHEMBL3550893 | 0.85 | CDC25A (0.60) | CDC25ACDC25BCDC25CMALT1MAOB | |
| SCHEMBL3548433 | 0.82 | CDC25A (0.64) | CDC25ACDC25BCDC25CMALT1CDK4 | |
| SCHEMBL3547085 | 0.81 | CDC25A (0.60) | CDC25ACDC25BCDC25CMALT1CDK4 | |
| SCHEMBL3553331 | 0.81 | CDC25A (0.60) | CDC25ACDC25BCDC25CMALT1CDK4 | |
| SCHEMBL3546656 | 0.80 | CDC25A (0.59) | CDC25ACDC25BCDC25CMALT1CDK4 | |
| SCHEMBL4650649 | 0.79 | CDC25A (0.41) | CDC25ACDC25BCDC25C | |
| SCHEMBL3552795 | 0.79 | CDC25A (0.60) | CDC25ACDC25BCDC25CMALT1CDK4 | |
| SCHEMBL5225917 | 0.79 | CDC25A (0.64) | CDC25ACDC25BCDC25CMALT1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795284-B2 | 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses | IPSEN PHARMA S.A.S. (FR) | 2010-09-14 | — | — | US | claimed |
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2007-10-18 | — | — | US | claimed |
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | CDC25C, CDC25A, CDC25B | CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885 |
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | CDC25C, CDC25A, CDC25B | CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.